Insider · CIK 0001781290

Hirawat Samit

Reports to the SEC for 3 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001781290

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-10	PCRXPacira BioSciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10.9K sh	—	—	10,891
2026-06-10	PCRXPacira BioSciences, Inc.A Award	Director	AAward	+6,405 sh	—	—	6,405
2026-01-27	PCRXPacira BioSciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+39.3K sh	—	—	39,291
2025-04-25	BMYBRISTOL MYERS SQUIBB COP Purchase	EVP,Chief Med.Offr.,Drug Dev.	PPurchase	+4,250 sh	$47.58	+$202K	83,513.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	+5,854 sh	—	—	73,929.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP,Chief Med.Offr.,Drug Dev.	FTax Payment	−2,013 sh	$63.11	−$127K	68,075.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	−998 sh	—	—	72,931.486
2025-03-10	BMYBRISTOL MYERS SQUIBB CO · Performance SharesA Award	EVP,Chief Med.Offr.,Drug Dev.	AAward	+52.7K sh	—	—	52,720
2025-03-10	BMYBRISTOL MYERS SQUIBB CO · Performance SharesM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−28.6K sh	—	—	0
2025-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsA Award	EVP,Chief Med.Offr.,Drug Dev.	AAward	+35.1K sh	—	—	35,146
2025-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−5,854 sh	—	—	11,711
2025-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−4,765 sh	—	—	4,767
2025-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−4,886 sh	—	—	0
2025-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP,Chief Med.Offr.,Drug Dev.	FTax Payment	−9,232 sh	$63.11	−$583K	79,263.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	−10.5K sh	—	—	88,495.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	+28.6K sh	—	—	99,040.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP,Chief Med.Offr.,Drug Dev.	FTax Payment	−2,484 sh	$63.11	−$157K	70,447.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	+4,886 sh	—	—	68,818.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	−337 sh	—	—	68,481.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP,Chief Med.Offr.,Drug Dev.	FTax Payment	−2,327 sh	$63.11	−$147K	66,154.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	+4,765 sh	—	—	70,919.486
2025-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	−831 sh	—	—	70,088.486
2025-02-14	BMYBRISTOL MYERS SQUIBB COP Purchase	EVP,Chief Med.Offr.,Drug Dev.	PPurchase	+1,823.486 sh	$54.84	+$100K	63,932.486
2024-11-01	BMYBRISTOL MYERS SQUIBB COP Purchase	EVP,Chief Med.Offr.,Drug Dev.	PPurchase	+1,830 sh	$54.67	+$100K	62,109
2024-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP,Chief Med.Offr.,Drug Dev.	FTax Payment	−9,774 sh	$53.79	−$526K	60,279
2024-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	+4,192 sh	—	—	51,437
2024-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	−660 sh	—	—	50,777
2024-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP,Chief Med.Offr.,Drug Dev.	FTax Payment	−1,807 sh	$53.79	−$97.2K	48,970
2024-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	+4,885 sh	—	—	53,855
2024-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	−842 sh	—	—	53,013
2024-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP,Chief Med.Offr.,Drug Dev.	FTax Payment	−2,068 sh	$53.79	−$111K	50,945
2024-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	+29.3K sh	—	—	80,256
2024-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	−10.2K sh	—	—	70,053
2024-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−4,192 sh	—	—	0
2024-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−4,885 sh	—	—	4,886
2024-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	−4,765 sh	—	—	9,532
2024-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	−5,854 sh	—	—	17,565
2024-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsA Award	EVP,Chief Med.Offr.,Drug Dev.	AAward	+40.6K sh	—	—	40,635
2024-03-10	BMYBRISTOL MYERS SQUIBB CO · Performance SharesM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−29.3K sh	—	—	0
2024-03-10	BMYBRISTOL MYERS SQUIBB CO · Performance SharesA Award	EVP,Chief Med.Offr.,Drug Dev.	AAward	+61K sh	—	—	60,952
2023-07-01	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	+9,357 sh	—	—	52,032
2023-07-01	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−9,357 sh	—	—	0
2023-07-01	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP,Chief Med.Offr.,Drug Dev.	FTax Payment	−4,787 sh	$63.95	−$306K	47,245
2023-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−4,189 sh	—	—	4,192
2023-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP,Chief Med.Offr.,Drug Dev.	FTax Payment	−2,540 sh	$65.71	−$167K	23,716
2023-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP,Chief Med.Offr.,Drug Dev.	JOther	+775 sh	—	—	26,256
2023-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	+4,189 sh	—	—	25,481
2023-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−4,885 sh	—	—	9,771
2023-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP,Chief Med.Offr.,Drug Dev.	MExercise/Conversion	−4,765 sh	—	—	14,297
2023-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsA Award	EVP,Chief Med.Offr.,Drug Dev.	AAward	+23.4K sh	—	—	23,419

Recent filings

Accepted (ET)
Jun 124
Hirawat Samit0001628280-26-043010
SEC(opens sec.gov)
Jan 294
Hirawat Samit0001628280-26-004188
SEC(opens sec.gov)
Apr 294
Hirawat Samit0000014272-25-000093
SEC(opens sec.gov)
Mar 124
Hirawat Samit0000014272-25-000063
SEC(opens sec.gov)

Companies

Address

C/O IAMBIC THERAPEUTICS, INC. 5627 OBERLIN DRIVE, SUITE 120

SAN DIEGO, CA, 92121